GenMark Diagnostics, Inc (NASDAQ:GNMK) has received an average rating of “Hold” from the nine analysts that are covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, three have given a hold recommendation and five have assigned a buy recommendation to the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $11.80.
Several analysts have issued reports on GNMK shares. Canaccord Genuity restated a “buy” rating and issued a $14.00 price objective on shares of GenMark Diagnostics in a research note on Monday, October 30th. Needham & Company LLC dropped their price objective on GenMark Diagnostics from $15.00 to $11.00 and set a “buy” rating on the stock in a research note on Friday, November 3rd. Raymond James Financial restated a “market perform” rating on shares of GenMark Diagnostics in a research note on Friday, November 3rd. Cowen restated a “buy” rating and issued a $10.00 price objective on shares of GenMark Diagnostics in a research note on Friday, November 3rd. Finally, Zacks Investment Research lowered GenMark Diagnostics from a “hold” rating to a “sell” rating in a research note on Tuesday, November 7th.
In other GenMark Diagnostics news, insider Hany Massarany sold 8,252 shares of the company’s stock in a transaction that occurred on Monday, November 20th. The stock was sold at an average price of $4.74, for a total value of $39,114.48. Following the sale, the insider now owns 362,957 shares in the company, valued at $1,720,416.18. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Insiders sold 21,651 shares of company stock worth $104,313 in the last 90 days. Corporate insiders own 7.50% of the company’s stock.
Shares of GenMark Diagnostics (NASDAQ GNMK) opened at $4.49 on Friday. GenMark Diagnostics has a twelve month low of $3.63 and a twelve month high of $13.67. The stock has a market capitalization of $260.28, a PE ratio of -3.68 and a beta of 0.78. The company has a current ratio of 2.97, a quick ratio of 2.77 and a debt-to-equity ratio of 0.12.
About GenMark Diagnostics
GenMark Diagnostics, Inc is a molecular diagnostics company. The Company is focused on developing and commercializing multiplex molecular tests that aid in the diagnosis of complex medical conditions. It develops and commercializes multiplex molecular tests based on its eSensor electrochemical detection technology.
Receive News & Ratings for GenMark Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GenMark Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.